At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Ethambutol +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus Controls
In Brief
A clinical study evaluating Ethambutol, Rifampin, and 2 other interventions for Cystic Fibrosis. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedFeb 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedFeb 26, 2015
Enrollment StartOct 1, 2014
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.3 years ago
Interventions
Ethambutoldrug
Anti-mycobacterial oral drug
Rifampindrug
Anti-mycobacterial oral drug
Azithromycindrug
Anti-mycobacterial oral drug
Pancrelipasedrug
Pancreatic enzyme replacement therapy